Core Laboratories N.V. Company Profile (NYSE:CLB)

Core Laboratories N.V. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CLB."

Core Laboratories N.V. announced a quarterly dividend on Thursday, July 6th. Stockholders of record on Monday, July 17th will be given a dividend of $0.55 per share on Monday, August 14th. This represents a $2.20 annualized dividend and a dividend yield of 2.46%. The ex-dividend date of this dividend is Thursday, July 13th. View Core Laboratories N.V.'s Dividend History.

Core Laboratories N.V. (NYSE:CLB) posted its quarterly earnings data on Monday, July, 24th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.51 by $0.01. The firm earned $163.90 million during the quarter, compared to the consensus estimate of $168.23 million. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The firm's revenue was up 10.7% compared to the same quarter last year. During the same period last year, the firm earned $0.35 earnings per share. View Core Laboratories N.V.'s Earnings History.

Core Laboratories N.V. is scheduled to release their next quarterly earnings announcement on Wednesday, October, 18th 2017. View Earnings Estimates for Core Laboratories N.V..

Core Laboratories N.V. updated its third quarter earnings guidance on Monday, July, 24th. The company provided EPS guidance of $0.54-0.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.61. The company issued revenue guidance of $165.5-170 million, compared to the consensus revenue estimate of $179.01 million.

13 analysts have issued 12 month price targets for Core Laboratories N.V.'s shares. Their forecasts range from $91.00 to $145.00. On average, they anticipate Core Laboratories N.V.'s share price to reach $118.00 in the next twelve months. View Analyst Ratings for Core Laboratories N.V..

Core Laboratories N.V. saw a increase in short interest in the month of July. As of July 14th, there was short interest totalling 10,107,975 shares, an increase of 39.4% from the June 30th total of 7,251,583 shares. Based on an average daily trading volume, of 1,767,144 shares, the days-to-cover ratio is currently 5.7 days. Currently, 23.3% of the shares of the stock are short sold.

Some companies that are related to Core Laboratories N.V. include RPC (RES), Antero Midstream GP LP (AMGP), Oceaneering International (OII), John Wood Group PLC (WG), McDermott International (MDR), Petrofac Limited (PFC), Frank's International N.V. (FI), Superior Energy Services (SPN), Tidewater (TDW), Forum Energy Technologies (FET), USA Compression Partners, LP (USAC), Archrock Partners, L.P. (APLP), Helix Energy Solutions Group (HLX), NCS Multistage Holdings (NCSM), Exterran Corporation (EXTN), Newpark Resources (NR), Archrock (AROC) and Fairmount Santrol Holdings (FMSA).

Core Laboratories N.V.'s management team includes the folowing people:

• David M. Demshur, Chairman of the Supervisory Board, President, Chief Executive Officer
• Richard L. Bergmark, Chief Financial Officer, Executive Vice President, Member of the Supervisory Board
• Monty L. Davis, Chief Operating Officer, Senior Vice President
• Christopher S. Hill, Vice President, Chief Accounting Officer
• Mark F. Elvig, Vice President, Secretary, General Counsel
• Gwendolyn Y. Schreffler, Vice President, Corporate Development & Investor Relations
• Martha Z. Carnes, Member of the Supervisory Board
• Charles L. Dunlap, Member of the Supervisory Board
• Jan Willem Sodderland, Member of the Supervisory Board
• Michael Straughen, Member of the Supervisory Board

Core Laboratories N.V.'s stock is owned by a number of of institutional and retail investors. Top institutional investors include WCM Investment Management CA (10.04%), Vanguard Group Inc. (8.32%), Sustainable Growth Advisers LP (5.31%), Earnest Partners LLC (4.16%), Kayne Anderson Rudnick Investment Management LLC (3.86%) and BlackRock Inc. (3.50%). Company insiders that own Core Laboratories N.V. stock include Jan Willem Sodderland, Martha Z Carnes and Michael Straughen. View Institutional Ownership Trends for Core Laboratories N.V..

Core Laboratories N.V.'s stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, RiverPark Advisors LLC, American Century Companies Inc., Macquarie Group Ltd., Jackson Square Partners LLC, Bank of Montreal Can, Wells Fargo & Company MN and Capital World Investors. View Insider Buying and Selling for Core Laboratories N.V..

Core Laboratories N.V.'s stock was bought by a variety of institutional investors in the last quarter, including Sustainable Growth Advisers LP, WCM Investment Management CA, Neuberger Berman Group LLC, Sei Investments Co., JPMorgan Chase & Co., Forsta AP Fonden, Vanguard Group Inc. and Northern Trust Corp. Company insiders that have bought Core Laboratories N.V. stock in the last two years include Jan Willem Sodderland, Martha Z Carnes and Michael Straughen. View Insider Buying and Selling for Core Laboratories N.V..

Shares of Core Laboratories N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Core Laboratories N.V. stock can currently be purchased for approximately $89.55.